A Phase I, Open-Label, Randomized, Single-Dose, Crossover Study to Evaluate Food Effect and Relative Bioavailability of ECC4703 Formulations (F0, F1, F2, and F3) in Healthy Adults
Latest Information Update: 20 Jan 2026
At a glance
- Drugs ECC-4703 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors Eccogene
Most Recent Events
- 20 Jan 2026 New trial record
- 16 Jan 2026 Planned initiation date changed from 1 Jan 2026 to 10 Jan 2026.